These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14566035)

  • 1. C-reactive protein and cardiovascular disease: new insights from an old molecule.
    Hirschfield GM; Pepys MB
    QJM; 2003 Nov; 96(11):793-807. PubMed ID: 14566035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein and atherothrombosis.
    Pepys MB; Hirschfield GM
    Ital Heart J; 2001 Mar; 2(3):196-9. PubMed ID: 11305531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory bio-markers and cardiovascular risk prediction.
    Blake GJ; Ridker PM
    J Intern Med; 2002 Oct; 252(4):283-94. PubMed ID: 12366601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein and its role in the pathogenesis of myocardial infarction.
    Pepys MB; Hirschfield GM
    Ital Heart J; 2001 Nov; 2(11):804-6. PubMed ID: 11770862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, atherosclerosis and cardiovascular disease. An update.
    Camici M
    Minerva Cardioangiol; 2002 Aug; 50(4):327-31. PubMed ID: 12147963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein as a novel biomarker. Reactant can flag atherosclerosis and help predict cardiac events.
    Elgharib N; Chi DS; Younis W; Wehbe S; Krishnaswamy G
    Postgrad Med; 2003 Dec; 114(6):39-44; quiz 16. PubMed ID: 14689723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The physiological structure of human C-reactive protein and its complex with phosphocholine.
    Thompson D; Pepys MB; Wood SP
    Structure; 1999 Feb; 7(2):169-77. PubMed ID: 10368284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.
    Hirschfield GM; Gallimore JR; Kahan MC; Hutchinson WL; Sabin CA; Benson GM; Dhillon AP; Tennent GA; Pepys MB
    Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8309-14. PubMed ID: 15919817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [C-reactive protein and atherosclerosis].
    Xie LQ; Wang X
    Sheng Li Ke Xue Jin Zhan; 2004 Apr; 35(2):113-8. PubMed ID: 15285415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.
    Maier W; Altwegg LA; Corti R; Gay S; Hersberger M; Maly FE; Sütsch G; Roffi M; Neidhart M; Eberli FR; Tanner FC; Gobbi S; von Eckardstein A; Lüscher TF
    Circulation; 2005 Mar; 111(11):1355-61. PubMed ID: 15753219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?
    Lagrand WK; Visser CA; Hermens WT; Niessen HW; Verheugt FW; Wolbink GJ; Hack CE
    Circulation; 1999 Jul; 100(1):96-102. PubMed ID: 10393687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events.
    Vainas T; Stassen FR; de Graaf R; Twiss EL; Herngreen SB; Welten RJ; van den Akker LH; van Dieijen-Visser MP; Bruggeman CA; Kitslaar PJ
    J Vasc Surg; 2005 Aug; 42(2):243-51. PubMed ID: 16102622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [C-reactive protein: cardiovascular issues of an acute-phase protein].
    Amezcua-Guerra LM; Springall del Villar R; Bojalil Parra R
    Arch Cardiol Mex; 2007; 77(1):58-66. PubMed ID: 17500194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein: a new golden marker of cardiovascular risk.
    Gomes MC
    Rev Port Cardiol; 2002 Nov; 21(11):1329-46. PubMed ID: 12564084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting C-reactive protein for the treatment of cardiovascular disease.
    Pepys MB; Hirschfield GM; Tennent GA; Gallimore JR; Kahan MC; Bellotti V; Hawkins PN; Myers RM; Smith MD; Polara A; Cobb AJ; Ley SV; Aquilina JA; Robinson CV; Sharif I; Gray GA; Sabin CA; Jenvey MC; Kolstoe SE; Thompson D; Wood SP
    Nature; 2006 Apr; 440(7088):1217-21. PubMed ID: 16642000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?
    Arici M; Walls J
    Kidney Int; 2001 Feb; 59(2):407-14. PubMed ID: 11168922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological actions of pentraxins.
    Vilahur G; Badimon L
    Vascul Pharmacol; 2015 Oct; 73():38-44. PubMed ID: 25962566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein in atherosclerosis: A causal factor?
    Paffen E; DeMaat MP
    Cardiovasc Res; 2006 Jul; 71(1):30-9. PubMed ID: 16624260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
    Norata GD; Garlanda C; Catapano AL
    Trends Cardiovasc Med; 2010 Feb; 20(2):35-40. PubMed ID: 20656213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of determination of the levels of phospholipase A2 in plasma lipoproteins and functional relations with C-reactive protein].
    Titov VN
    Klin Lab Diagn; 2010 Aug; (8):3-16. PubMed ID: 20891039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.